Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01823991 · ClinicalTrials.gov registry record · Early Phase 1
COGNUTRIN in Breast Cancer Survivors
A Early Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
NCT01823991 is a Early Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 36 participants.
The verdict
NCT01823991, a Early Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and influence of an intervention (COGNUTRIN) using nutritional supplements (n-3 fatty acids and blueberry anthocyanins) on cognitive performance in breast cancer survivors following chemotherapy. The investigators' goal is to treat or lessen the late effects of cancer treatment. The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
Interventions
- OTHER Placebo
- DRUG Lovaza®
- DRUG VitaBlue™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-07-30 |
| Est. Completion | 2018-05-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01823991
The ClinicalTrials.gov registry entry for NCT01823991 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01823991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01823991 about?
NCT01823991 is a clinical study titled "COGNUTRIN in Breast Cancer Survivors". The purpose of this study is to examine the safety and influence of an intervention (COGNUTRIN) using nutritional supplements (n-3 fatty acids and blueberry anthocyanins) on cognitive performance in breast cancer survivors following chemotherapy. The investigators' goal is to treat or lessen the lat...
What is the current status of trial NCT01823991?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2014-07-30. Estimated completion is 2018-05-02.
What interventions are being tested in trial NCT01823991?
The interventions under investigation include: Placebo (OTHER), Lovaza® (DRUG), VitaBlue™ (DRUG).
Who is sponsoring clinical trial NCT01823991?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.